Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02643693 · ClinicalTrials.gov registry record · NA
User Acceptability of a Nicotine Lactate Delivery System (P3L)
A NA study, sponsored by Philip Morris Products S.A..
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT02643693 is a NA study that has completed, run by Philip Morris Products S.A.. The registered enrollment target is 24 participants.
The verdict
NCT02643693, a NA study, has completed, sponsored by Philip Morris Products S.A..
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will provide an initial assessment of the acceptability of the Nicotine Lactate Delivery System (P3L) after ad libitum use and the ability of combustible cigarette (CC) smokers to use P3L to maintain their customary nicotine intake, in a manner comparable with their own brand of CC or the VUSE e-cigarette system.
Interventions
- OTHER CC
- OTHER P3L
- OTHER VUSE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02643693
The ClinicalTrials.gov registry entry for NCT02643693 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Philip Morris Products S.A., which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CC is the first listed.
NCT02643693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02643693 about?
NCT02643693 is a clinical study titled "User Acceptability of a Nicotine Lactate Delivery System (P3L)". This study will provide an initial assessment of the acceptability of the Nicotine Lactate Delivery System (P3L) after ad libitum use and the ability of combustible cigarette (CC) smokers to use P3L to maintain their customary nicotine intake, in a manner comparable with their own brand of CC or the...
What is the current status of trial NCT02643693?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2015-11. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02643693?
The interventions under investigation include: CC (OTHER), P3L (OTHER), VUSE (OTHER).
Who is sponsoring clinical trial NCT02643693?
This trial is sponsored by Philip Morris Products S.A., which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.